Boulder, Colo., based Array BioPharma has announced topline results from a phase II, double-blind, randomized, placebo-controlled study of selumetinib (AZD6244) in patients with KRAS-mutant, locally advanced or metastatic non-small cell lung cancer.
The trial sought to determine whether selumetinib plus docetaxel was superior to docetaxel alone as a second-line therapy against that patient group in terms of overall survival.
Selumetinib is a MEK inhibitor that Array licensed to AstraZeneca, and it was AstraZeneca that carried out the trial.
The trial featured 87 patients, and unfortunately selumetinib plus docetaxel did not outperform docetaxel alone, at least in numbers that reached statistical significance. However, secondary endpoints—such as progression-free survival, objective response rate, and alive and progression-free at 6 months—were shown to be statistically significant.
This data will be presented at a forthcoming scientific conference.
Several other currently ongoing clinical trials are testing the anti-cancer efficacy of selumetinib (AZD6244).
Further Reading
Array News Release
Clinical Trial # NCT00890825
Bekaii-Saab T et al. Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers . JCO June 10, 2011 vol. 29 no. 17 2357-2363.
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
